Journal articleBone Marrow Transplant · June 2025
Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effe ...
Full textLink to itemCite
Journal articleAnn Surg Oncol · April 2025
BACKGROUND: Although high treatment costs of breast cancer care are well documented, the relationship between delayed/forgone (D/F) care and resource utilization among patients with breast cancer is unknown. This study sought to investigate the relationshi ...
Full textLink to itemCite
Journal articleJCO Oncol Pract · January 2025
Financial toxicity (FT) is now a well-recognized issue affecting many patients with cancer and their families. The field is rapidly moving from a focus on describing this problem to efforts to optimize screening and identify management solutions. There are ...
Full textLink to itemCite
Journal articleJ Pain Symptom Manage · December 2024
CONTEXT: Prognostication challenges contribute to delays in advance care planning (ACP) for patients with cancer near the end of life (EOL). OBJECTIVES: Examine a quality improvement mortality prediction algorithm intervention's impact on ACP documentation ...
Full textLink to itemCite
Journal articleJCO Oncol Pract · March 2024
PURPOSE: We investigated the prevalence of financial toxicity in a population undergoing hematopoietic cell transplantation (HCT) evaluation and measured its impact on post-transplant clinical and health-related quality-of-life outcomes. MATERIALS AND METH ...
Full textLink to itemCite
Journal articleOncologist · August 3, 2023
This commentary reflects on the decade since the publication of an article on the financial toxicity of cancer treatment and the international recognition of the scope and depth of the problem, in the hope that the coming decade is characterized by evaluat ...
Full textLink to itemCite
Journal articleAm J Surg · April 2023
BACKGROUND: We sought to identify modifiable factors associated with cancer screening in a community-based health assessment. METHODS: 24 organizations at 47 community events in central North Carolina distributed a 91-item survey from April-December 2017. ...
Full textLink to itemCite
Journal articleJ Surg Res · April 2023
INTRODUCTION: We sought to examine patient and provider perspectives regarding modifiable contributors to breast cancer treatment and to assess perceptual alignment between these two groups. MATERIALS: Participants were women≥18 y with stage 0-IV breast ca ...
Full textLink to itemCite
Journal articleSupport Care Cancer · October 2022
PURPOSE: Mobile health interventions can improve patient care. We developed the Digital Supportive Care Awareness and Navigation (D-SCAN) application (app) to facilitate symptom monitoring and use/awareness of cancer supportive care resources. This study t ...
Full textLink to itemCite
Journal articleTrials · August 26, 2022
BACKGROUND: For patients and their intimate partners, advanced cancer poses significant challenges that can negatively impact both individuals and their relationship. Prior studies have found evidence that couple-based communication skills interventions ca ...
Full textLink to itemCite
Journal articlePatient Educ Couns · August 2022
OBJECTIVES: Clinicians increasingly believe they should discuss costs with their patients. We aimed to learn what strategies clinicians, clinic leaders, and health systems can use to facilitate vital cost-of-care conversations. METHODS: We conducted focus ...
Full textLink to itemCite
Journal articleJ Natl Cancer Inst Monogr · July 5, 2022
With rising health-care costs and increasing patient financial strain, health economics research has never been more relevant to the lay public. This manuscript summarizes the discussion from the "Communicating Health Economics Research to Non-Researcher A ...
Full textLink to itemCite
Journal articleJAMA Netw Open · June 1, 2022
IMPORTANCE: High-deductible health plans (HDHPs) require high upfront cost-sharing, which has been associated with suboptimal anticancer medication uptake and adherence. Whether HDHP enrollment has limited the affordability and use of lenalidomide therapy ...
Full textLink to itemCite
Journal articleSupport Care Cancer · April 2022
INTRODUCTION: Cancer patients' sources of distress are often unaddressed, and patient-reported distress data could be utilized to identify those with unmet and impending care needs. We explored the association between moderate/severe distress and healthcar ...
Full textLink to itemCite
Journal articleTrends Cancer · April 2022
Rising costs of cancer care drive patient financial toxicity (FT) that perpetuates known health disparities in access and quality cancer treatment. This Review discusses how FT is a barrier to cancer research and treatment, and discusses potential solution ...
Full textLink to itemCite
Journal articleBMC Fam Pract · November 18, 2021
BACKGROUND: As treatments for cancer have improved, more people are surviving cancer. However, compared to people without a history of cancer, cancer survivors are more likely to die of cardiovascular disease (CVD). Increased risk for CVD-related mortality ...
Full textLink to itemCite
Journal articleJCO Oncol Pract · October 2021
PURPOSE: Insured patients with cancer face high treatment-related, out-of-pocket (OOP) costs and often cannot access financial assistance. We conducted a randomized, controlled trial of Bridge, a patient-facing app designed to identify eligible financial r ...
Full textLink to itemCite
Journal articleJCO Glob Oncol · September 2021
PURPOSE: The social impact of cancer on patients and their family is well known. Yet, unlike with physical and financial toxicities, no validated tools are available to measure this impact. This study aimed at developing, validating, and implementing a nov ...
Full textLink to itemCite
Journal articleAm Heart J · August 2021
Cardiovascular disease (CVD) is a major source of financial burden and distress, which has 3 main domains: (1) psychological distress; (2) cost-related care non-adherence or medical care deferral, and (3) tradeoffs with basic non-medical needs. We propose ...
Full textLink to itemCite
Journal articleOncologist · June 2021
LESSONS LEARNED: Antitumor activity was observed in the study population. Dose modifications of cabozantinib improve long-term tolerability. Biomarkers are needed to identify patient populations most likely to benefit. Further study of cabozantinib with or ...
Full textLink to itemCite
Journal articleJCO Oncol Pract · June 2021
PURPOSE: Although financial toxicity is a well-documented aspect of cancer care, little is known about how patients narratively characterize financial experiences related to breast cancer treatment. We sought to examine these patient experiences through mi ...
Full textLink to itemCite
Journal articleN Engl J Med · April 1, 2021
BACKGROUND: No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. METHODS: We conducted CheckMate 577, a global, ra ...
Full textLink to itemCite
Journal articleCA Cancer J Clin · March 2021
Cancer treatment is associated with financial hardship for many patients and families. Screening for financial hardship and referrals to appropriate resources for mitigation are not currently part of most clinical practices. In fact, discussions regarding ...
Full textLink to itemCite
Journal articleN C Med J · 2021
BACKGROUND Patients with cancer are at risk for both objective and subjective financial distress. Financial distress during treatment is adversely associated with physical and mental well-being. Little is known about whether patients' subjective financial ...
Full textLink to itemCite
Journal articleFront Psychol · 2021
Cancer and its treatment pose challenges that affect not only patients but also their significant others, including intimate partners. Accumulating evidence suggests that couples' ability to communicate effectively plays a major role in the psychological a ...
Full textLink to itemCite
Journal articleJ Natl Cancer Inst · August 1, 2020
BACKGROUND: Health reform and the merits of Medicaid expansion remain at the top of the legislative agenda, with growing evidence suggesting an impact on cancer care and outcomes. A systematic review was undertaken to assess the association between Medicai ...
Full textLink to itemCite
Journal articleJ Natl Compr Canc Netw · July 2020
BACKGROUND: Financial distress from medical treatment is an increasing concern. Healthcare organizations may have different levels of organizational commitment, existing programs, and expected outcomes of screening and management of patient financial distr ...
Full textLink to itemCite
Journal articleJCO Clin Cancer Inform · January 2020
PURPOSE: More than 20% of US clinical trials fail to accrue sufficiently. Our purpose was to provide a benchmark for better understanding clinical trial enrollment feasibility and to assess relative levels of competition for patients by cancer diagnosis. M ...
Full textOpen AccessLink to itemCite
Journal articleBMC Cancer · November 1, 2019
BACKGROUND: Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose (R ...
Full textLink to itemCite
Journal articleCancer Chemother Pharmacol · October 2019
PURPOSE: This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with ...
Full textLink to itemCite
Journal articleJ Oncol Pract · August 2019
PURPOSE: Financial toxicity is a well-recognized adverse effect of cancer care, yet little is known about how women consider treatment costs when facing preference-sensitive decisions for breast cancer surgery or how surgical treatment choice affects finan ...
Full textLink to itemCite
Journal articleJ Cancer Educ · June 2019
Cancer survivorship care plans (SCPs) are endorsed to support quality care for cancer survivors, but uptake is slow. We assessed knowledge, needs, and preferences for SCP content and delivery from a wide variety of stakeholders. We focused SCP content for ...
Full textOpen AccessLink to itemCite
Journal articleAm Soc Clin Oncol Educ Book · January 2019
Financial barriers to clinical trial enrollment are an area of active investigation. Financial toxicity as a concept describes how high costs and financial burden can lead to compromised care and outcomes. Despite the potential to yield large survival bene ...
Full textLink to itemCite
Journal articleCancer · November 15, 2018
BACKGROUND: Place of death is an essential component of high quality cancer care and comprehensive national trends and disparities in place of death are unknown. METHODS: Deidentified death certificate data were obtained via the National Center for Health ...
Full textLink to itemCite
Journal articleSurg Oncol Clin N Am · October 2018
In the age of ever-expanding treatments and precision medicine, the hope for cure remains the ultimate goal for patients and providers. Equally important to many patients is the quality of life achieved during and after treatment. Evidence suggests that ov ...
Full textLink to itemCite
Journal articleCancer Med · September 2018
BACKGROUND: Increasing attention is being paid to financial burdens of cancer survivorship, but little is known about the prevalence and predictors of these burdens in older, long-term survivors. METHODS: We used data from 6012 participants diagnosed with ...
Full textLink to itemCite
Journal articleJ Oncol Pract · September 2018
PURPOSE: Patients with cancer are at risk for substantial treatment-related costs; however, little is known about patients' willingness to sacrifice to receive cancer care and how their attitudes and burden may change with time. PATIENTS AND METHODS: We co ...
Full textLink to itemCite
Journal articleOncologist · July 2018
PURPOSE: This study evaluated the maximum tolerated dose or recommended phase II dose (RPTD) and safety and tolerability of the ganitumab and everolimus doublet regimen followed by the ganitumab, everolimus, and panitumumab triplet regimen. MATERIALS AND M ...
Full textLink to itemCite
Journal articleJ Natl Cancer Inst · July 1, 2018
Because of the rising costs of cancer care and ongoing challenges in ensuring access to quality care, there is an increasing need to prioritize spending and define the benefits of therapy in proportion to costs. The term "value" has gained favor as means t ...
Full textLink to itemCite
Journal articleAnn Transl Med · May 2018
Molecular and immune therapies have revolutionized cancer treatment and improved patient outcomes and survival. However, the pricing of these drugs has become an issue as the cost of cancer care continues to rise significantly. Cost sharing policies have i ...
Full textLink to itemCite
Journal articleJ Oncol Pract · February 2018
PURPOSE: The Affordable Care Act (ACA) aimed to increase insurance coverage through key provisions such as expansion of Medicaid eligibility and enforcement of an individual mandate. The objective of this study is to examine the impact of the ACA on insura ...
Full textLink to itemCite
Journal articleN C Med J · 2018
Out-of-pocket spending continues to increase, particularly in cancer care. High out-of-pocket expenditures are associated with increased psychosocial distress, lower adherence, and higher mortality. In order to improve cancer-related outcomes, we must come ...
Full textLink to itemCite
Journal articleFront Psychol · 2018
Cancer treatment poses significant challenges not just for those diagnosed with the disease but also for their intimate partners. Evidence suggests that couples' communication plays a major role in the adjustment of both individuals and in the quality of t ...
Full textOpen AccessLink to itemCite
Journal articleJ Oncol Pract · November 2017
PURPOSE: ASCO identified oncologist-patient conversations about cancer costs as an important component of high-quality care. However, limited data exist characterizing the content of these conversations. We sought to provide novel insight into oncologist-p ...
Full textLink to itemCite
Journal articleJAMA Oncol · November 1, 2017
This cross-sectional survey study examines financial distress and cost expectations among patients with cancer presenting for anticancer therapy. ...
Full textLink to itemCite
Journal articlePsychooncology · July 2017
OBJECTIVE: This study aims to test the feasibility and preliminary efficacy of a couple-based communication intervention for advanced GI cancer delivered via videoconference. METHODS: Thirty-two couples were randomly assigned to either couples communicatio ...
Full textLink to itemCite
Journal articleCancer · April 15, 2017
BACKGROUND: Short-course radiotherapy (SC-RT) and long-course chemoradiotherapy (LC-CRT) are accepted neoadjuvant treatments of rectal cancer. In the current study, the authors surveyed US radiation oncologists to assess practice patterns and attitudes reg ...
Full textLink to itemCite
Journal articleJ Manag Care Spec Pharm · April 2017
BACKGROUND: Limited transparency exists regarding eligibility and benefits for patient financial assistance programs (PAPs). OBJECTIVE: To describe oral anticancer medication costs, insurance coverage, and the degree of financial assistance provided by PAP ...
Full textLink to itemCite
Journal articleJ Oncol Pract · March 2017
OBJECTIVE: Pharmaceutical manufacturers sponsor drug-specific patient assistance programs that provide eligible patients with financial assistance, either in the form of providing the drug free of charge or copayment assistance. Describing these programs a ...
Full textLink to itemCite
Journal articleAm Soc Clin Oncol Educ Book · 2017
The median price of a month of chemotherapy has increased by an order of magnitude during the past 20 years, far exceeding inflation over the same period. Along with rising prices, increases in cost sharing have forced patients to directly shoulder a great ...
Full textLink to itemCite
Journal articleJ Glob Oncol · December 2016
PURPOSE: Global cancer burden has increasingly shifted to low- and middle-income countries and is particularly pronounced in Africa. There remains a lack of comprehensive cancer information as a result of limited cancer registry development. In Moshi, Tanz ...
Full textOpen AccessLink to itemCite
Journal articleOncologist · October 2016
A dramatic rise in the costs of health care—and cancer care in particular—has occurred over the last decade. Increasingly, these costs are being passed on to patients in the form of cost sharing, which can have a catastrophic effect on the financial well-b ...
Full textLink to itemCite
Journal articlePsychooncology · June 2016
BACKGROUND: Cancer patients may experience financial distress as a side effect of their care. Little is known about which patients are at greatest risk for altering their care or lifestyle due to treatment-related financial distress. METHODS: We conducted ...
Full textLink to itemCite
Journal articleJ Pain Symptom Manage · June 2016
CONTEXT: Palliative care (PC) consultation services are available in most hospitals; outpatient services are rapidly growing to meet the needs of patients at earlier stages of the disease trajectory. OBJECTIVES: We aimed to compare the unmet needs of PC pa ...
Full textLink to itemCite
Journal articleJ Clin Oncol · May 20, 2016
PURPOSE: To measure the association between patient financial strain and symptom burden and quality of life (QOL) for patients with new diagnoses of lung or colorectal cancer. PATIENTS AND METHODS: Patients participating in the Cancer Care Outcomes Researc ...
Full textLink to itemCite
Journal articleJ Natl Cancer Inst · May 2016
Evidence suggests that a considerably large proportion of cancer patients are affected by treatment-related financial harm. As medical debt grows for some with cancer, the downstream effects can be catastrophic, with a recent study suggesting a link betwee ...
Full textLink to itemCite
Journal articleJ Oncol Pract · March 2016
PURPOSE: We surveyed US cancer doctors to examine current attitudes toward cost discussions and how they influence decision making and practice management. METHODS: We conducted a self-administered, anonymous, electronic survey of randomly selected physici ...
Full textLink to itemCite
Journal articleEur Heart J · January 21, 2016
AIMS: Studies have suggested increased cancer incidence associated with long-term dual antiplatelet therapy (DAPT) for acute coronary syndrome (ACS). We evaluated cancer incidence and treatment-related differences in an analysis of DAPT for ACS. METHODS AN ...
Full textLink to itemCite
Journal articleValue Health · January 2016
Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sha ...
Full textLink to itemCite
Journal articleAm J Manag Care · September 2015
OBJECTIVES: Patients with cancer can experience substantial financial burden. Little is known about patients' preferences for incorporating cost discussions into treatment decision making or about the ramifications of those discussions. The objective of th ...
Link to itemCite
Journal articleBr J Cancer · June 30, 2015
BACKGROUND: Best supportive care (BSC) as a control arm in clinical trials is poorly defined. We conducted a review to evaluate clinical trials' concordance with published, consensus-based framework for BSC delivery in trials. METHODS: A consensus-based De ...
Full textLink to itemCite
Journal articleJAMA Intern Med · May 2015
IMPORTANCE: For patients with limited prognosis, some medication risks may outweigh the benefits, particularly when benefits take years to accrue; statins are one example. Data are lacking regarding the risks and benefits of discontinuing statin therapy fo ...
Full textLink to itemCite
Journal articleJ Oncol Pract · March 2015
PURPOSE: The impact of financial burden among patients with cancer has not yet been measured in a way that accounts for inter-relationships between quality of life, perceived quality of care, disease status, and sociodemographic characteristics. PATIENTS A ...
Full textLink to itemCite
Journal articleExpert Rev Gastroenterol Hepatol · 2015
Obesity/higher BMI appears to be important determinants in the development of colon cancer as well as in predicting outcomes in the adjuvant setting in these patients. These associations seem to be stronger for men and tend to be 'J-shaped', with worse out ...
Full textLink to itemCite
Journal articleFuture Oncol · November 2014
Advances in cancer diagnosis and treatment have led to increased societal costs and out-of-pocket patient cost. We reviewed the literature on the impact of out-of-pocket cancer care costs on the patient experience, and described efforts made to address the ...
Full textLink to itemCite
Journal articleJ Clin Oncol · October 1, 2014
PURPOSE: To identify insured services that are most important to Medicare beneficiaries with cancer and their family caregivers when coverage is limited. METHODS: A total of 440 participants (patients, n = 246; caregivers, n = 194) were enrolled onto the C ...
Full textLink to itemCite
Journal articleJ Oncol Pract · September 2014
PURPOSE: Cancer treatment-related out-of-pocket costs create substantial financial distress for many patients. However, little work has been done to describe available financial resources and barriers to connecting those resources to patients. METHODS: Thi ...
Full textLink to itemCite
Journal articleInvest New Drugs · August 2014
PURPOSE: To define maximum tolerated dose (MTD), toxicities, and pharmacodynamics of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumor patients. DESIGN: This was a standard "3 + 3" dose-escalation trial. All subjects received b ...
Full textLink to itemCite
Journal articleBMC Health Serv Res · July 19, 2014
BACKGROUND: Concerns about unsustainable costs in the US Medicare program loom as the number of retirees increase and experiences serious and costly illnesses like cancer. Engagement of stakeholders, particularly cancer patients and their families, in prio ...
Full textLink to itemCite
Journal articleInfectious Agents and Cancer · May 20, 2014
Background: In low- and middle-income countries, the association between delay to treatment and prognosis for Kaposi's sarcoma (KS) patients is yet to be studied. Methods. This is a prospective study of HIV-infected adults with histologically-confirmed KS ...
Full textCite
Journal articleJ Oncol Pract · May 2014
BACKGROUND: Little is known about the association between patient-oncologist discussion of cancer treatment out-of-pocket (OOP) cost and medication adherence, a critical component of quality cancer care. METHODS: We surveyed insured adults receiving antica ...
Full textLink to itemCite
Journal articleOncologist · April 2014
BACKGROUND: Health care-related costs and satisfaction are compelling targets for quality improvement in cancer care delivery; however, little is known about how financial burden affects patient satisfaction. METHODS: This was an observational, cross-secti ...
Full textLink to itemCite
Journal articleInvest New Drugs · April 2014
PURPOSE: Dasatinib inhibits src family kinases and has anti-angiogenic properties. We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC). M ...
Full textLink to itemCite
Journal articleJ Clin Oncol · March 10, 2014
PURPOSE: High-quality supportive care is an essential component of comprehensive cancer care. We implemented a patient-centered quality of cancer care survey to examine and identify predictors of quality of supportive care for bowel problems, pain, fatigue ...
Full textLink to itemCite
Journal articleLancet Oncol · March 2014
Comparative effectiveness research aims to inform health-care decisions by patients, clinicians, and policy makers. However, questions related to what information is relevant, and how to view the relative attributes of alternative interventions have politi ...
Full textLink to itemCite
Journal articleSemin Radiat Oncol · January 2014
Comparative effectiveness research (CER) is critically needed in medical oncology to improve the care being delivered to oncology patients. As medical oncologists are forced to rely on insufficient data as a part of daily treatment decision making, and as ...
Full textLink to itemCite
Journal articleInfect Agent Cancer · 2014
BACKGROUND: In low- and middle-income countries, the association between delay to treatment and prognosis for Kaposi's sarcoma (KS) patients is yet to be studied. METHODS: This is a prospective study of HIV-infected adults with histologically-confirmed KS ...
Full textLink to itemCite
Journal articleJ Oncol Pract · November 2013
The authors found that cost-related medication nonadherence was prevalent among patients with cancer who sought financial assistance. ...
Full textLink to itemCite
Journal articleJ Natl Compr Canc Netw · April 1, 2013
Clinical practice guidelines can be used to help develop measures of quality of cancer care. This article describes the use of a Cancer Care Quality Measurement System (CCQMS) to monitor these measures for colorectal cancer in the Veterans Health Administr ...
Full textLink to itemCite
Journal articleJ Oncol Pract · March 2013
PURPOSE: Only 2% to 5% of adult patients with cancer enroll onto clinical trials. We assessed simultaneously characteristics of patients and their physicians that may be independently associated with participation. METHODS: CanCORS, a National Cancer Insti ...
Full textLink to itemCite
Journal articleCancer · February 15, 2013
Featured Work
BACKGROUND: The objective of this study was to determine how patient preferences guide the course of palliative chemotherapy for advanced colorectal cancer. METHODS: Eligible patients with metastatic colorectal cancer (mCRC) were enrolled nationwide in a p ...
Full textLink to itemCite
Journal articlePsychooncology · January 2013
Featured Work
BACKGROUND: We measured the prevalence of stigma, self-blame, and perceived blame from others for their illness among men with colorectal cancer (CRC) and examined whether these factors were associated with depressive symptoms, independent of clinical and ...
Full textLink to itemCite
Journal articleOncologist · 2013
Featured Work
PURPOSE: Cancer patients carry rising burdens of health care-related out-of-pocket expenses, and a growing number of patients are considered "underinsured." Our objective was to describe experiences of insured cancer patients requesting copayment assistanc ...
Full textLink to itemCite
Journal articleOncologist · 2013
Featured Work
BACKGROUND: Esophageal and gastric cancers often present at an advanced stage. Systemic chemotherapy is the mainstay of treatment, but survival with current regimens remains poor. We evaluated the safety, tolerability, and efficacy of the combination capec ...
Full textLink to itemCite
Journal articleWorld Health Popul · 2013
Cancer burden is increasing in Africa more than in any other continent, but population-based tracking of cancer incidence is incomplete. Cancer registries can improve understanding of cancer incidence. To assess organizational readiness to sustain registry ...
Full textLink to itemCite
Journal articleN Engl J Med · October 4, 2012
BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, ...
Full textLink to itemCite
Journal articleCancer Chemother Pharmacol · August 2012
Featured Work
PURPOSE: To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus, and panobinostat (LBH-589) when administered in combination to patients with advanced solid tumor malignancies. EXPERIMENT DESIGN: Subjects ...
Full textLink to itemCite
Journal articleCancer Chemother Pharmacol · July 2012
Featured Work
PURPOSE: Preclinical data suggest concurrent inhibition of VEGF, mTOR and EGFR pathways may augment antitumor and antiangiogenic effects compared to inhibition of each pathway alone. This study evaluated the maximum tolerated dose/recommended phase II dose ...
Full textLink to itemCite
Journal articleAnn Surg Oncol · May 2012
Featured Work
BACKGROUND: Ampullary carcinoma is a rare malignancy. Despite radical resection, survival rates remain low with high rates of local failure. We performed a single-institution outcomes analysis to define the role of concurrent chemoradiotherapy (CRT) in add ...
Full textLink to itemCite
Journal articleJ Pain Symptom Manage · May 2012
Featured Work
CONTEXT: In specialist hospice and palliative care services, variations occur in diagnoses and prognoses of subpopulations referred, service configuration, and the health systems delivering care. These three levels of variation limit the ability to general ...
Full textLink to itemCite
Journal articleCurr Opin Support Palliat Care · March 2012
Featured Work
PURPOSE OF REVIEW: This review summarizes recent developments in the management of gastrointestinal symptoms experienced by cancer patients and provides a framework for education, assessment and monitoring, and treatment. RECENT FINDINGS: Although many via ...
Full textLink to itemCite
Journal articleLancet Oncol · February 2012
Featured Work
Best supportive care is poorly defined in clinical trials, and a standard framework for delivery of such care is needed, using best available evidence and allowing replication of studies. We convened a panel of 36 experts to develop consensus statements vi ...
Full textLink to itemCite
Journal articleBMC Cancer · August 16, 2011
Featured Work
BACKGROUND: We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment. METHODS: We analyzed patient surveys and medical records for a population-based cohort with metastatic colorectal cancer treat ...
Full textLink to itemCite
Journal articleCancer Chemother Pharmacol · February 2011
Featured Work
PURPOSE: VEGF, mTOR, and EGFR inhibitors have demonstrated anti-tumor and anti-angiogenic effects alone and in combination with each other. This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus, and erlotinib combin ...
Full textLink to itemCite
Journal articleCancer Manag Res · 2011
Featured Work
5-Fluorouracil has been a mainstay in the treatment of colorectal cancer for nearly five decades; however, the use of oral formulations of the medication has been gaining increasing traction since capecitabine was approved for use in adjuvant settings by t ...
Full textLink to itemCite
Journal articleOncologist · 2011
Featured Work
PURPOSE: For patients with metastatic colorectal cancer (mCRC), no standard therapy exists after progression on 5-fluorouracil, oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab. Preclinical data demonstrated that combined vascular endothe ...
Full textLink to itemCite
Journal articleJ Palliat Med · December 2010
Featured Work
BACKGROUND: Palliative medicine has made rapid progress in establishing its scientific and clinical legitimacy, yet the evidence base to support clinical practice remains deficient in both the quantity and quality of published studies. Historically, the co ...
Full textOpen AccessLink to itemCite
Journal articleJ Pain Symptom Manage · October 2010
Featured Work
CONTEXT: The Patient Care Monitor (PCM) is a review of systems survey delivered by means of an electronic patient-reported outcomes (ePRO) data capture system that uses wireless tablet computers. Although the PCM 1.0 is validated, the updated PCM 2.0 has n ...
Full textLink to itemCite
Journal articleJ Palliat Med · August 2010
Featured Work
BACKGROUND: Outpatient palliative care, an evolving delivery model, seeks to improve continuity of care across settings and to increase access to services in hospice and palliative medicine (HPM). It can provide a critical bridge between inpatient palliati ...
Full textOpen AccessLink to itemCite
Journal articleJ Clin Oncol · July 1, 2010
Featured Work
PURPOSE: The Veterans Affairs (VA) healthcare system treats approximately 3% of patients with cancer in the United States each year. We measured the quality of nonmetastatic colorectal cancer (CRC) care in VA as indicated by concordance with National Compr ...
Full textLink to itemCite
Journal articleMed Care · June 2010
Featured Work
BACKGROUND: "Rapid learning healthcare" presents a new infrastructure to support comparative effectiveness research. By leveraging heterogeneous datasets (eg, clinical, administrative, genomic, registry, and research), health information technology, and so ...
Full textLink to itemCite
Journal articleCurr Opin Support Palliat Care · March 2010
Featured Work
PURPOSE OF REVIEW: Gastrointestinal symptoms are prevalent, often persistent, and detrimental to patients' quality of life. This review discusses evaluation of gastrointestinal symptoms as patient-reported outcomes (PROs) and presents an information techno ...
Full textLink to itemCite
Journal articleJ Clin Oncol · February 1, 2010
Featured Work
PURPOSE: To describe chemotherapy use and adverse events (AEs) for advanced-stage, non-small-cell lung cancer (NSCLC) in community practice, including descriptions according to variation by age. METHODS: We interviewed patients with newly diagnosed, stages ...
Full textLink to itemCite
Journal articleCancer J · 2010
Featured Work
This review aims to describe available standards for delivery of palliative and supportive care for cancer patients and discuss to what extent these guidelines have been evaluated and disseminated into standard care. Ovid searches were conducted to identif ...
Full textLink to itemCite
Journal articleJ Support Oncol · 2010
Featured Work
As survival of metastatic colorectal cancer (mCRC) increases, patients have more exposure to chemotherapy and related toxicity. The objective is to determine how toxicity patterns affect care. Via a population-based strategy, mCRC cases diagnosed between J ...
Link to itemCite
Journal articleJ Clin Oncol · November 10, 2009
Featured Work
PURPOSE: To systematically review the best supportive care (BSC) literature and to evaluate the ethical and methodologic validity issues by using widely acknowledged criteria. METHODS: Two search strings that included both cancer and supportive as terms (w ...
Full textLink to itemCite
Journal articleJ Oncol Pract · September 2009
Featured Work
Multiple agents and combination therapies available to patients with advanced colorectal cancer have significantly improved survival and provided an opportunity for individualization of care, allowing clinicians and patients to prioritize risks and benefit ...
Full textLink to itemCite
Journal articleSupport Care Cancer · June 2009
Featured Work
GOALS: Management of the risk of potential chemotherapy-induced neutropenic complications such as febrile neutropenia (FN) and severe neutropenia (SN) is a quality of care priority. How frequently does care at our institution conform to established guideli ...
Full textLink to itemCite
Journal articleJ Clin Oncol · May 20, 2009
4080 Background: For patients (pts) with mCRC, no standard therapy exists after progression on 5-FU, oxaliplatin, irinotecan, bevacizumab, and/or cetuximab/panitumumab. Preclinical data demonstrate combined VEGF and mTOR inhibition has greater anti-angioge ...
Link to itemCite
Journal articleJ Clin Oncol · May 20, 2009
6522 Background: In a "learning healthcare system" clinical decisions are supported by accurate information delivered at point of care; information gathered today iteratively informs future care and research. METHODS: Customized software on wireless tablet ...
Link to itemCite
Journal articleCurr Opin Support Palliat Care · March 2009
Featured Work
PURPOSE OF REVIEW: This review summarizes recent developments in the palliative management of gastrointestinal symptoms experienced by advanced cancer patients and provides a framework for detailing that encompasses education, assessment and monitoring, an ...
Full textLink to itemCite
Journal articleSupport Care Cancer · February 2009
Featured Work
INTRODUCTION: Complexity in decision making for cancer treatment arises from many factors. When considering how to treat patients, physicians prioritize factors such as stage of disease, patient age, and comorbid illnesses. However, physicians must balance ...
Full textLink to itemCite
Journal articleJ Support Oncol · 2009
Featured Work
Notebook-style computers (e/Tablets) are increasingly replacing paper methods for collecting patient-reported information. Discrepancies in data between these methods have been found in oncology for sexuality-related questions. A study was performed to for ...
Link to itemCite
Journal articleBMC Cancer · November 25, 2008
Featured Work
BACKGROUND: Stage at diagnosis plays a significant role in colorectal cancer (CRC) survival. Understanding which factors contribute to a more advanced stage at diagnosis is vital to improving overall survival. Comorbidity, race, and age are known to impact ...
Full textOpen AccessLink to itemCite
Journal articleBMC Cancer · November 25, 2008
Background: Stage at diagnosis plays a significant role in colorectal cancer (CRC) survival. Understanding which factors contribute to a more advanced stage at diagnosis is vital to improving overall survival. Comorbidity, race, and age are known to impact ...
Full textCite
Journal articleOncologist · July 2008
Featured Work
With improving survival following solid organ transplantation, clinicians must be aware of post-transplant complications. One increasingly frequent complication is the development of malignancy after transplantation. The most common malignancies encountere ...
Full textLink to itemCite